141 related articles for article (PubMed ID: 14652795)
1. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis.
Bagnato F; Durastanti V; Finamore L; Volante G; Millefiorini E
Neurol Sci; 2003 Dec; 24 Suppl 5():S301-4. PubMed ID: 14652795
[TBL] [Abstract][Full Text] [Related]
2. [Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].
Halota W; Jaruga B; Pawłowska M
Pol Merkur Lekarski; 2002 Aug; 13(74):126-8. PubMed ID: 12420343
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.
Sorensen PS; Tscherning T; Mathiesen HK; Langkilde AR; Ross C; Ravnborg M; Bendtzen K
Neurology; 2006 Nov; 67(9):1681-3. PubMed ID: 17101906
[TBL] [Abstract][Full Text] [Related]
4. Interferon inhibitory activity in patients with multiple sclerosis.
Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
[TBL] [Abstract][Full Text] [Related]
5. [Neopterin: a marker used for monitoring infections].
Cesur S
Mikrobiyol Bul; 2005 Apr; 39(2):251-60. PubMed ID: 16128038
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A
Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
[TBL] [Abstract][Full Text] [Related]
7. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
Chowdhury SA; Lin J; Sadiq SA
Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
[TBL] [Abstract][Full Text] [Related]
8. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
[TBL] [Abstract][Full Text] [Related]
9. [Urinary excretion of neopterin and plasma levels of interferon gamma in patients with multiple myeloma].
Spicka I; Tomsová Z; Masek Z; Procházka B; Zounar R; Klener P
Vnitr Lek; 1996 Oct; 42(10):665-8. PubMed ID: 8975455
[TBL] [Abstract][Full Text] [Related]
10. Effect of cladribine treatment on beta-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis.
Niezgoda A; Losy J; Mehta PD
Folia Morphol (Warsz); 2001 Aug; 60(3):225-8. PubMed ID: 11552664
[TBL] [Abstract][Full Text] [Related]
11. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging monitoring of multiple sclerosis lesion evolution.
Inglese M; Grossman RI; Filippi M
J Neuroimaging; 2005; 15(4 Suppl):22S-29S. PubMed ID: 16385016
[TBL] [Abstract][Full Text] [Related]
13. [Modifications of the lipid metabolism induced by interferon beta in multiple sclerosis patients and its relationship with the disease activity].
Ara JR; López A; Martín J; Alarcia R; Oliván JA; de Val V
Neurologia; 2004 Sep; 19(7):359-63. PubMed ID: 15273882
[TBL] [Abstract][Full Text] [Related]
14. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.
Rovaris M; Barkhof F; Calabrese M; De Stefano N; Fazekas F; Miller DH; Montalban X; Polman C; Rocca MA; Thompson AJ; Yousry TA; Filippi M
Neurology; 2009 May; 72(19):1693-701. PubMed ID: 19433744
[TBL] [Abstract][Full Text] [Related]
15. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
16. High sensitivity measurement of CRP and disease progression in multiple sclerosis.
Soilu-Hänninen M; Koskinen JO; Laaksonen M; Hänninen A; Lilius EM; Waris M
Neurology; 2005 Jul; 65(1):153-5. PubMed ID: 16009907
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis.
Kuenz B; Lutterotti A; Khalil M; Ehling R; Gneiss C; Deisenhammer F; Reindl M; Berger T
J Neuroimmunol; 2005 Oct; 167(1-2):143-9. PubMed ID: 16040131
[TBL] [Abstract][Full Text] [Related]
18. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.
Rentzos M; Cambouri C; Rombos A; Nikolaou C; Anagnostouli M; Tsoutsou A; Dimitrakopoulos A; Triantafyllou N; Vassilopoulos D
J Neurol Sci; 2006 Feb; 241(1-2):25-9. PubMed ID: 16316662
[TBL] [Abstract][Full Text] [Related]
19. The importance of patient monitoring in clinical cytokine trials: use of serum markers to define biologically active doses.
Huber C; Herold M
Cancer Surv; 1989; 8(4):809-15. PubMed ID: 2518331
[TBL] [Abstract][Full Text] [Related]
20. [Neopterin and its importance in clinical diagnosis].
Melichar B
Cas Lek Cesk; 1994 Aug; 133(15):455-8. PubMed ID: 8082110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
